Cost-minimization analysis for Portugal of five doublet chemotherapy regimens from two phase III trials in the treatment of advanced non-small cell lung cancer

Lung Cancer

Volumn 52, Issue 3, 2006, Pages 365-371

  Pimentel, F L ^a   Bhalla, S ^b   Laranjeira, L ^c   Guerreiro, M ^c  

^a Hospital So Sebastio   (Portugal)

^b ELI LILLY AND COMPANY   (United States)

^c Lilly Portugal Produtos Farmacêuticos ^*  (Portugal)

Author keywords

Cisplatin; Cost minimization; Gemcitabine; Non small cell lung cancer

Indexed keywords

ANTINEOPLASTIC AGENT; CARBOPLATIN; CISPLATIN; DOCETAXEL; GEMCITABINE; NAVELBINE; PACLITAXEL;

ADVANCED CANCER; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; COMPARATIVE STUDY; CONTROLLED STUDY; COST MINIMIZATION ANALYSIS; COST OF ILLNESS; DISEASE SEVERITY; DRUG COST; DRUG DOSE REGIMEN; DRUG EFFICACY; ECONOMIC EVALUATION; HEALTH CARE COST; HOSPITALIZATION; HUMAN; LUNG NON SMALL CELL CANCER; PORTUGAL; PRIORITY JOURNAL; REIMBURSEMENT; SENSITIVITY ANALYSIS; TREATMENT INDICATION;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CARBOPLATIN; CARCINOMA, NON-SMALL-CELL LUNG; CISPLATIN; CLINICAL TRIALS, PHASE III; COSTS AND COST ANALYSIS; DEOXYCYTIDINE; FEMALE; HUMANS; LUNG NEOPLASMS; MALE; NATIONAL HEALTH PROGRAMS; PACLITAXEL; PORTUGAL; TAXOIDS;

EID: 33747783988     PISSN: 01695002     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.lungcan.2006.03.005     Document Type: Article

References (14)

1. World Health Organization. European health for all database (HFA-DB); 2001.
2. Comella P., Frasci G., Panza N., Manzione L., De Cataldis G., Cioffi R., et al. Randomized trial comparing cisplatin, gemcitabine, and vinorelbine with either cisplatin and gemcitabine or cisplatin and vinorelbine in advanced non-small-cell lung cancer: interim analysis of a phase III trial of the Southern Italy Cooperative Oncology Group. J Clin Oncol 18 (2000) 1451-1457
3. Schiller J.H., Harrington D., Belani C.P., Langer C., Sandler A., Krook J., et al. Comparison of four chemotherapy regimens for advanced non-small-cell lung cancer. N Engl J Med 346 (2002) 92-98
4. Schiller J., Tilden D., Aristides M., Lees M., Kielhorn A., Maniadakis N., et al. Retrospective cost analysis of gemcitabine in combination with cisplatin in non-small cell lung cancer compared to other combination therapies in Europe. Lung Cancer 43 (2004) 101-112
5. Diagnosis Related Groups (DRG) published at Diário da República; February 2003.
6. Cat@logo de Aprovisionamento Público da Saúde; 2003. Available from: http://www.catalogo.min-saude.pt/CAPS/publico/default.asp.
7. National Therapeutic Index, Portugal; 2003.
8. Chu E., and De Vita V. Cancer Chemotherapy Drug Manual (2005), Jones and Bartlett publishers, Sudbury, Massachussetts
9. Souquet P.J., Chauvin F., Boissel J.P., Cellerino R., Cormier Y., Ganz P.A., et al. Polychemotherapy in advanced non small cell lung cancer: a meta-analysis. Lancet 342 (1993) 19-21
10. Non-Small Cell Lung Cancer Collaborative Group. Chemotherapy in non-small cell lung cancer: a meta-analysis using updated data on individual patients from 52 randomised clinical trials. BMJ 311 (1995) 899-909
11. Manegold C. Gemcitabine (Gemzar) in non-small cell lung cancer. Expert Rev Anticancer Ther 4 (2004) 345-360
12. Manegold C., Zatloukal P., Krejcy K., and Blatter J. Gemcitabine in non-small cell lung cancer (NSCLC). Invest New Drugs 18 (2000) 29-42
13. Sandler A.B., Nemunaitis J., Denham C., von Pawel J., Cormier Y., Gatzemeier U., et al. Phase III trial of gemcitabine plus cisplatin versus cisplatin alone in patients with locally advanced or metastatic non-small-cell lung cancer. J Clin Oncol 18 (2000) 122-130
14. Le Chevalier T., Scagliotti G., Natale R., Danson S., Rosell R., Stahel R., et al. Efficacy of gemcitabine plus platinum chemotherapy compared with other platinum containing regimens in advanced non-small cell lung cancer: a meta-analysis of survival outcomes. Lung Cancer 47 (2005) 69-80